| scholarly article | Q13442814 |
| P2093 | author name string | Richard B Moss | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| teenager | Q1492760 | ||
| P304 | page(s) | 55-63 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis | |
| P478 | volume | 121 |
| Q34508730 | (99m)Tc-labeled therapeutic inhaled amikacin loaded liposomes |
| Q80403102 | A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study |
| Q36891530 | Advancing outcome measures for the new era of drug development in cystic fibrosis |
| Q92739425 | Airway regeneration using iPS cell-derived airway epithelial cells with Cl- channel function |
| Q35012425 | Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents |
| Q24188054 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis |
| Q38821019 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. |
| Q44512892 | Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis |
| Q30448377 | Clinical experimentation with aerosol antibiotics: current and future methods of administration |
| Q37364113 | Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency |
| Q38367260 | Clinical pharmacokinetics of inhaled antimicrobials. |
| Q27014993 | Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy |
| Q51673689 | Composite Spirometric–Computed Tomography Outcome Measure in Early Cystic Fibrosis Lung Disease |
| Q24612271 | Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa |
| Q38690137 | Cystic fibrosis: current therapeutic targets and future approaches. |
| Q45088972 | Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis |
| Q34004443 | Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa |
| Q33244220 | Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation |
| Q40290246 | Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success? |
| Q41071899 | Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study |
| Q22306312 | Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis |
| Q37700304 | Inhaled anti-infective agents: emphasis on colistin |
| Q24235635 | Inhaled antibiotics for long-term therapy in cystic fibrosis |
| Q33640488 | Inhaled antibiotics for lower airway infections. |
| Q58094329 | Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis |
| Q24202283 | Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis |
| Q35925366 | Inhaled therapeutics for prevention and treatment of pneumonia |
| Q26797450 | Inhaled therapy in cystic fibrosis: agents, devices and regimens |
| Q35580478 | Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis |
| Q33811280 | Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis |
| Q36627996 | Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. |
| Q43406723 | Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. |
| Q41703064 | Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). |
| Q38384994 | Long-term safety and efficacy of tobramycin in the management of cystic fibrosis |
| Q85115976 | Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects |
| Q35026630 | Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis |
| Q24247996 | Nebulised anti-pseudomonal antibiotics for cystic fibrosis |
| Q36310044 | Nebulized antibiotic therapy: the evidence |
| Q34706830 | Nebulized antibiotics in cystic fibrosis |
| Q37609433 | Optimizing treatment policies and improving care: impact on outcome in patients with cystic fibrosis |
| Q37333170 | Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection |
| Q40887035 | Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients |
| Q46876081 | Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. |
| Q37129932 | Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection |
| Q39761233 | Predictors of deterioration of lung function in Polish children with cystic fibrosis |
| Q41834845 | Real-world challenges to the practice of evidence-based medicine |
| Q33861117 | Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial |
| Q36750086 | The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections |
| Q34566912 | The rationale for aerosolized antibiotics |
| Q61912424 | Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics |
| Q37940005 | Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis |
| Q37980230 | Tobramycin for the treatment of bacterial pneumonia in children |
| Q38630919 | Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis |
| Q33957168 | Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial |
| Q38160206 | Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis |
| Q61809676 | Tobramycin reduces key virulence determinants in the proteome of Pseudomonas aeruginosa outer membrane vesicles |
| Q54318026 | Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis. |
| Q35908307 | Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies |
| Q93063101 | Unusual Cystic Fibrosis Transmembrane Conductance Regulator Mutations and Liver Disease: A Case Series and Review of the Literature |
| Q37608274 | Update on antibiotics for infection control in cystic fibrosis |
| Q35176271 | Versatility of aminoglycosides and prospects for their future |
| Q50484768 | [Aminoglycosides]. |
| Q80781978 | [Will we still have antibiotics tomorrow?] |
Search more.